McDermott Will & Emery is pleased to present a complimentary, topical webinar in its regular Life Sciences series. A number of significant pharmaceutical and medical device industry players have used merger inversion transactions for strategic acquisitions of non-U.S. companies, resulting in significantly reduced post-acquisition effective tax rates. In a merger inversion transaction, the domicile of the merged company is located outside of the U.S. These transactions have also given the acquirers new access to life sciences technologies. This webinar will examine the benefits and risks involved in merger inversion transactions in the pharmaceutical and medical device industry.